FDA Expands Recall Of Multiple Blood Pressure Medications
PITTSBURGH (KDKA)-- Torrent Pharmaceuticals Limited has expanded its recall for Losartan Potassium Tablets USP and Losartan Potassium/hydrochlorothiazide tablets for all consumers.
The FDA reported that traces of unexpected impurities, N-Methylnitrosobutyric acid (NMBA), were found in batches manufactured with active pharmaceutical ingredients.
Losartan is used to treat patients with Left Ventricular Hypertrophy and nephropathy in Type 2 diabetics.
The products included in the expanded recall are listed below:
| NDC | Product Name, Strength and Package Count | Batch Number | Expiration Date |
| 13668-409-10 | Losartan Potassium Tablets, USP 50mg, 1000 count | 4DU2E009 | 12/31/2020 |
| 13668-115-90 | Losartan Potassium Tablets, USP 100mg, 90 count | 4DU3E009 | 12/31/2020 |
| 13668-115-10 | Losartan Potassium Tablets, USP 100mg, 1000 count | 4DU3E018 | 02/28/2021 |
| 13668-116-90 | Losartan Potassium / Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 90 count | BEF7D051 | 11/30/2020 |
| 13668-118-90 | Losartan Potassium / Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count. | 4P04D007 | 07/31/2020 |
Torrent Pharmaceuticals Limited is notifying its distributors and customers by phone and in writing to immediately discontinue distribution of the specific lots being recalled and to notify their sub-accounts.
This is the 5th expansion recall for the drugs.
Officials urge patients to contact their health physician or pharmacist to receive alternative treatment before returning their medication. Consumers should also contact a doctor if they have experienced any health issues that may be related to these drugs.
Click here, for more information on the recall.
